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Innovative therapeutic agents have significantly improved outcome with an acceptable 
safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, 
who depend on oncogenic molecular alterations for their malignant phenotype. Despite 
the survival improvement achieved with first-line chemotherapy, about 30% of patients 
do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, 
acquire resistance and develop tumor progression after a median of about 5 months. 
Approximately 60% of the patients progressing from first-line chemotherapy receive fur-
ther systemic treatment in the second-line setting. Moreover, new options have emerged 
in the second-line armamentarium for the treatment of patients with NSCLC, including 
immune checkpoint inhibitors and antiangiogenic agents. The current review provides 
an overview on the clinical studies that gained the approval of chemotherapy agents 
(docetaxel and pemetrexed) and epidermal growth factor receptor gene–tyrosine kinase 
inhibitors as second-line treatment options for NSCLC patients, not carrying molecular 
alterations.
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iNTRODUCTiON
Lung cancer is the leading cause of cancer death in the world (1) and non-small cell lung cancer 
(NSCLC) accounts for approximately 85% of cases. The majority of patients are diagnosed with 
advanced or metastatic disease. Despite the progresses in the treatment of NSCLC, the prognosis 
remains poor, with an estimated 5 years overall survival (OS) of only 16%.
For a long time, platinum doublet chemotherapy has been the standard first-line treatment option 
for NSCLC patients (2, 3). Until 2005, treatment choice was mainly based on the distinction between 
NSCLC and small cell lung cancer. The approval of bevacizumab in 2006 (4, 5) and pemetrexed in 
2008 (6) raised the issue that discriminating between squamous and non-squamous histology was a 
crucial element for therapeutic selection, since bevacizumab and pemetrexed can be administered 
to patients with non-squamous tumors only, for safety and efficacy reasons.
During the past 10 years, thanks to the technological advances, our knowledge on NSCLC tumor 
biology has improved (7). Different driver molecular alterations, responsible for the development 
of oncogene-addicted NSCLC tumors, have been identified, especially in the subgroup of patients 
with adenocarcinoma (8–12). Currently, NSCLC is not considered a single homogenous entity, but 
as a heterogeneous disease, including rare molecularly classified lung tumors, that are susceptible to 
targeted inhibition (13–17). Patients who carry activating mutations in the epidermal growth factor 
TabLe 1 | Clinical trials exploring second-line chemotherapy.
Study Treatment N of 
pts
Major toxicities Progression-
free survival HR 
(95%Ci)
Overall survival HR 
(95% Ci)
TAX317 (20) Docetaxel (100 or 75 mg/m2) vs best supportive 
care
103 Leukopenia, neutropenia, hair loss – p = 0.01
TAX320 (21) Docetaxel (100 or 75 mg/m2) vs vinorelbine or 
ifosfamide
373 Leukopenia, neutropenia, hair loss for 
docetaxel
p = 0.005 5.5 vs 5.7 m (NS)
DISTAL-01 
(22)
Docetaxel (75 mg/m2 q21) vs docetaxel (33 mg/
m2 weekly)
Weekly: non-neutropenic infection – HR 1.04 (0.77–1.39) 
p = 0.803-weekly: leukopenia, neutropenia, hair loss
JMEI (23) Pemetrexed (500 mg/m2) vs docetaxel (75 mg/m2) Leukopenia, neutropenia, hair loss for 
docetaxel
HR 0.97 
(0.82–1.16)
HR 0.99 (0.8–1.20)
NS, not significant; HR, hazard ratio.
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receptor gene (EGFR) or translocations in the anaplastic lym-
phoma kinase gene are treated with their specific tyrosine kinase 
inhibitors (TKIs), while platinum-based doublet chemotherapy 
with or without bevacizumab remains the first-line standard of 
care for patients in whom no molecular alteration is identified.
Despite the survival improvement achieved with first-line 
chemotherapy (18), about 30% of patients do not obtain a 
tumor response. Moreover, those patients, initially sensitive to 
treatment, acquire resistance and develop tumor progression 
after a median of about 5  months (19). Approximately 60% of 
the patients progressing from first-line chemotherapy receive 
further systemic treatment in the second-line setting. Currently, 
second-line therapy is based on docetaxel, pemetrexed, erlotinib, 
nivolumab, or the combination of docetaxel with nintedanib or 
ramucirumab. The current review provides an overview on the 
clinical studies that gained the approval of chemotherapy agents 
and EGFR–TKIs as second-line treatment options for NSCLC 
patients, not carrying molecular alterations.
DOCeTaXeL aND PeMeTReXeD
The TAX317 study (20) was the first phase III trial showing a 
survival advantage of second-line chemotherapy in NSCLC 
patients, previously treated with platinum-based regimen 
(Table  1). One hundred three patients, stratified according 
to Eastern Cooperative Oncology Group performance status 
(ECOG PS) and best response to first-line chemotherapy, were 
randomized between two different doses of docetaxel (100 and 
75  mg/m2) and best supportive care. Docetaxel was associated 
with significantly longer OS and time to progression (TTP), com-
pared with best supportive care. The advantage was significantly 
greater in the group receiving docetaxel at the dose of 75  mg/
m2, probably due to the higher frequency of febrile neutropenia 
and deaths observed in patients under treatment with 100 mg/
m2. These results were confirmed by the phase III TAX320 study 
(Table 1), which compared docetaxel at the dose of 100 or 75 mg/
m2, with vinorelbine or ifosfamide in 373 NSCLC patients, who 
had previously failed platinum-containing chemotherapy (21). 
Docetaxel was associated with longer TTP and progression-free 
survival (PFS). Even though OS did not differ between the three 
regimens, a significant greater percentage of patients receiving 
docetaxel at the dose of 75 mg/m2 was alive during the first year, 
compared with those randomized in the vinorelbine or ifosfa-
mide arms (Table 1). Based on these data, docetaxel at the dose of 
75 mg/m2 has become the reference control arm for second-line 
chemotherapy for patients with advanced NSCLC.
With the aim to reduce the frequency of grade 3–4 hema-
tologic adverse events, observed in a high proportion of the 
patients enrolled in the TAX317 and TAX 320 trials (54 and 67%, 
respectively) (20, 21), two docetaxel schedules (75 mg/m2 admin-
istered every 3 weeks and 33.3 mg/m2 administered weekly) were 
investigated in the phase III DISTAL-1 study (Table  1) (22). 
No significant difference was observed in terms of OS or global 
quality of Life (QoL), even though the weekly docetaxel resulted 
in significantly lower incidence of leukopenia, neutropenia, and 
hair loss, but higher occurrence of non-neutropenic infections. 
Moreover, an improvement in some of the QoL items, such as pain 
and cough, were reported with the weekly regimen (Table 1). In 
order to better compare the efficacy and the safety profile of the 
weekly and three-weekly docetaxel regimens, an individual patient 
data meta-analysis, including three phase III and two phase II 
randomized trials, enrolling 865 patients, was performed (24). No 
difference in terms of OS or objective response rate (ORR) was 
found, but a significant advantage in terms of severe and febrile 
neutropenia was confirmed in favor of the weekly schedule, thus 
suggesting that weekly docetaxel represents a valid alternative to 
the three-weekly administration (Table 1).
Another therapeutic opportunity in the second-line setting is 
represented by the antifolate pemetrexed (25). Based on the results 
of a phase III trial, showing the non-inferiority of pemetrexed in 
terms of PFS, OS, and ORR and a more favorable toxicity profile 
over docetaxel, with fewer grade 3–4 neutropenia and febrile neu-
tropenia (23), in 2004, pemetrexed was approved in the USA and 
Europe for the second-line treatment of patients with advanced 
NSCLC (Table 1). A previous retrospective analysis, focusing on 
the toxicities observed in 246 patients treated between 1995 and 
1999 with pemetrexed, indicated that high pretreatment plasma 
homocysteine levels were associated with severe toxicity. This 
finding suggested that decreasing homocysteine levels, through 
the use of folate and vitamin B12 supplementation, would have 
improved pemetrexed safety profile without decreasing its effi-
cacy (26). The favorable toxicity profile of pemetrexed was con-
firmed in the subset analysis performed in 86 out of 571 patients 
with ≥70 years, enrolled in the phase III registration trial (27). 
TabLe 2 | Clinical trials exploring epidermal growth factor receptor gene–tyrosine kinase inhibitors with second-line chemotherapy.
Study Treatment N of 
pts
Major toxicities Progression-free survival HR 
(95%Ci)
Overall survival HR (95% Ci)
BR.21 (30) Erlotinib vs best supportive care 731 Skin rash, diarrhea HR 0.61 (0.51–0.74) p < 0.001 HR 0.70 (0.58–0.85) p < 0.001
TITAN (35) Erlotinib vs docetaxel or pemetrexed 424 Skin rash, diarrhea for erlotinib – HR 0.96 (0.78–1.19) p = 0.73
DELTA (36) Erlotinib vs docetaxel 301 HR 1.22 (0.97–1.55) p = 0.09 HR 0.91 (0.68–1.22) p = 0.53
TAILOR (37) Docetaxel vs erlotinib 222 Leukopenia, neutropenia, hair 
loss for docetaxel
HR 0.71 (0.53–0.95) p = 0.02 HR 0.73 (0.53–1.0) p = 0.05
PROSE (38) Docetaxel or pemetrexed vs erlotinib 285 HR = 1.35 (1.05–1.73) p = 0.020 HR = 1.22 (0.93–1.59) p = 0.148 
HORG (39) Erlotinib vs pemetrexed 322 Skin rash, diarrhea for erlotinib p = 0.136 p = 0.986
LUX-LUNG 
8 (40)
Afatinib vs erlotinib 795 Skin rash, diarrhea HR 0.82 (0.68–1.0) p = 0.04 HR 0.81 (0.69–0.95) p = 0.01
3
Lazzari et al. Second-Line Treatment for NSCLC Patients
Frontiers in Medicine | www.frontiersin.org January 2017 | Volume 4 | Article 4
A following phase III study, exploring cisplatin–pemetrexed as 
a first-line option, showed that pemetrexed is more effective in 
patients with non-squamous histology, due to the low expression 
of thymidylate synthase, a gene involved in the synthesis of folate 
and responsible for pemetrexed resistance in patients with lung 
squamous tumors (6, 28). Accordingly, the second-line indication 
for pemetrexed was revised to include patients with advanced 
non-squamous histology only.
In order to improve the therapeutic options, several trials have 
explored the efficacy and safety of doublet chemotherapy. An 
individual patient data analysis, including 847 patients, enrolled 
in six randomized trials (four phase II and two phase III), com-
paring mono-chemotherapy with doublet chemotherapy, was 
performed (29). Even though there was a statistically significant 
PFS improvement (of about 2  weeks) and a double RR with 
combination regimen, no survival prolongation was observed. 
These findings do not appear clinically relevant, and mono-
chemotherapy has remained the standard of care for second-line 
treatment.
CHeMOTHeRaPY OR eGFR–TKis iN 
SeCOND-LiNe SeTTiNG
In 2005, the phase III BR.21 trial (Table 2) compared the efficacy 
of the EGFR–TKI erlotinib with best supportive care in previ-
ously treated 731 advanced NSCLC patients, with ECOG PS 
0-3. Significant improvement in terms of OS, PFS, and QoL was 
observed in the erlotinib arm (30). For a long time, the identifi-
cation of molecular and clinical features, able to predict which 
patients could benefit more from EGFR–TKIs, has been the 
focus of much research. Based on the clinical data from patients, 
enrolled in the BR.21 trial, who early progressed (<8 weeks), or 
died (within 3 months from randomization) under erlotinib, a 
prognostic score, including 10 factors (smoking history, ECOG 
PS, weight loss, anemia, lactic dehydrogenase, response to prior 
chemotherapy, time from diagnosis, number of prior regimens, 
EGFR copy, and ethnicity), was built (31). Only 10% of the patients 
were classified in the low risk group and had high significant sur-
vival advantage with erlotinib over placebo. Moreover, the retro-
spective analysis of Kirsten rat sarcoma viral oncogene homolog, 
EGFR mutations, and EGFR gene copy number by fluorescence 
in  situ hybridization (FISH) showed that EGFR mutations and 
high copy number were predictive of response to erlotinib, but 
only EGFR FISH resulted as a significant predictive marker of dif-
ferential survival benefit (32). Despite EGFR activating mutations 
being identified in 2004 (8, 33), their role, as predictive biomark-
ers of sensitivity to EGFR–TKIs, was recognized only in 2009, 
following the results from the phase III IPASS study. The study 
reported a significant PFS and ORR advantage of gefitinib over 
platinum-based first-line chemotherapy in EGFR mutant patients 
and a detrimental effect in the EGFR wild-type subgroup (34). 
These findings shifted the development of EGFR–TKIs toward 
the first-line treatment of EGFR oncogene-addicted tumors and 
raised the question if erlotinib was an appropriate therapeutic 
option for EGFR wild-type patients or patients with unknown 
molecular status in the second-line setting. Other considerations 
include understanding the differences between QoL and toxic-
ity profile for EGFR–TKIs in comparison to standard of care in 
second-line and beyond.
Erlotinib has advantages in terms of toxicity, route of admin-
istration, and QoL. Its efficacy was compared with docetaxel and 
pemetrexed in different Phase III trials. Even though these studies 
had a different statistical design, the results were similar.
The TITAN trial (Table 2) was designed to demonstrate a 25% 
improvement in median OS of erlotinib vs chemotherapy (doc-
etaxel and pemetrexed) in 648 unselected NSCLC patients, who 
had progressed during first-line platinum doublet chemotherapy 
(35). Due to the slow accrual, the trial was prematurely closed, 
enrolling 424 patients only. No significant difference in terms of 
OS or PFS was seen between erlotinib and chemotherapy. Tumor 
samples were mandatory to enter the trial, and EGFR mutation 
status was available in 160 of the enrolled patients. Comparable 
OS and PFS were observed in the EGFR wild-type subgroup 
under chemotherapy or erlotinib.
These results were partly confirmed by the DELTA and the 
HORG studies (Table 2). The primary objective of the DELTA 
trial was to show 1-month PFS superiority of erlotinib over 
docetaxel in unselected second- or third-line 301 Asian NSCLC 
patients (36). Even though no significant difference was observed 
in terms of PFS and OS, docetaxel statistically prolonged PFS in 
the EGFR wild-type subgroup (199 patients out of 255 analyzed). 
However, this improvement did not translate into longer survival. 
The HORG study randomized 322 NSCLC patients, previously 
progressed to one or two chemotherapy lines, between erlotinib 
and pemetrexed (39). Squamous histology was not an exclusion 
criterion and the primary end-point was TTP. There was no dif-
ference in terms of TTP, ORR, or OS between the two treatment 
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arms. EGFR mutations were analyzed in 123 patients, and no 
OS, TTP, or ORR difference was observed, but EGFR wild-type 
patients had higher disease control rate under pemetrexed over 
erlotinib.
In contrast with the other studies, significantly longer PFS and 
OS (at the adjusted multivariate analysis) were found in favor of 
docetaxel in the 222 EGFR wild-type patients, enrolled in the 
TAILOR trial (Table  2), whose primary objective was to show 
14% OS improvement at 1  year of docetaxel over erlotinib in 
EGFR wild-type NSCLC patients (37). The cross-over treatment 
in further lines was not allowed and only taxane-naïve patients 
were included. These differences might have influenced the OS 
results.
Finally, the PROSE study (Table  2) randomized 285 unse-
lected second-line NSCLC patients, who were blinded classified 
according to a serum proteomic algorithm (the VeriStrat® test), 
previously developed, with the aim to identify patients who could 
benefit from EGFR–TKIs (38, 41). Patients were stratified by 
the proteomic algorithm, ECOG PS, and smoking history. The 
primary end-point was OS, and the primary hypothesis was to 
demonstrate the existence of a significant interaction between 
the proteomic classification and treatment efficacy. The VeriStrat® 
test is a multivariate biomarker, developed using eight m/z ratio 
mass spectrometric peaks. It classifies patients into two groups 
(good and poor), according to the clinical outcome observed 
under treatment with EGFR–TKIs. The results from the PROSE 
study were comparable to previous reports and showed that the 
PFS was longer in patients receiving chemotherapy, while no OS 
difference was found in the intent to treat analysis. The VeriStrat® 
test was prognostic, since good classified patients had better OS 
and PFS than poor classified ones. Furthermore, while good-
classified patients derived similar OS benefit from erlotinib and 
chemotherapy, VeriStrat poor-patients had significantly shorter 
OS under erlotinib, suggesting that the algorithm was also pre-
dictive of differential OS benefit between erlotinib and chemo-
therapy. EGFR mutations were analyzed in 176 patients included 
in the primary analysis, 14 of whom carried EGFR mutations. No 
statistical significant interaction was observed between VeriStrat 
classification and the EGFR mutation status, and comparable PFS 
and OS results were found in the EGFR wild-type subgroup. The 
prognostic and predictive role of the VeriStrat® test was also ret-
rospectively evaluated in 441 patients from the BR.21 trial (42). 
VeriStrat results demonstrated prognostic for OS and PFS, and 
predictive of response, but not predictive of differential benefit 
from erlotinib vs placebo.
Several meta-analyses have been performed to address the 
issue about the efficacy of EGFR–TKIs or chemotherapy in 
the second-line setting for the treatment of EGFR wild-type 
patients or patients with unknown molecular status. Recently, a 
meta-analysis, including 10 randomized trials and 1,119 EGFR 
wild-type patients, showed a significant PFS improvement for 
chemotherapy compared with EGFR–TKI therapy, with no OS 
difference (43). These results were confirmed by an individual 
patient data analysis, not yet published, and presented at ASCO 
in 2015, including 587 EGFR wild-type patients, enrolled in 
TAIOLR, DELTA, and PROSE studies. Chemotherapy deter-
mined longer PFS, which did not translate into longer OS.
Based on these findings, there are sufficient evidences sug-
gesting that, in EGFR wild-type patients with good ECOG PS, 
chemotherapy determines a greater disease control, although 
with more toxicity and without increasing survival.
Results from PROSE might partly explain as to which factors 
can contribute to the discrepancy observed between PFS and OS. 
One possible explanation is that, since poor classified patients 
have a detrimental effect under erlotinib, they do not benefit 
from third-line chemotherapy, and this determines shorter OS. 
Conversely, in good classified patients, erlotinib does not worsen 
their clinical conditions, allowing them to take advantage from 
further lines, thus influencing survival. Considering that 30% 
of NSCLC patients are classified as poor, it is possible that in an 
unselected population, the OS difference between chemotherapy 
and erlotinib does not emerge. The biological rationale behind 
the proteomic status is currently the subject of research. Four out 
of the eight m/z peaks composing the VeriStrat poor profile are 
generated by Serum Amiloid A1 (SAA-1) and its two truncated 
forms (44). Moreover, in VeriStrat poor classified patients, higher 
level of a panel of anti-inflammatory proteins (haptoglobin, 
SAA2, SAA3, α1-antitripsyn, and α1-antichimotrypsin) was 
observed. SAA1 is an acute-phase protein, and it is a non-specific 
tumor prognostic marker (45, 46). It is induced by interleukin 1 
(IL-1), interleukin 6 (IL-6), and tumor necrosis factor α (TNFα) 
(47). Data from literature showed that IL-6 reduced the sensitiv-
ity to erlotinib in NSCLC cells harboring EGFR mutations, due 
to an increased autocrine stimulation of the IL-6/gp130/signal 
transducer and activator of transcription 3 (STAT3) pathway 
(46). IL-6 activates the janus (JAK) and the Src kinases, which 
are responsible for the phosphorylation on the tyrosine 705 of the 
STAT3. Once phosphorylated, STAT3 translocates to the nucleus 
and activates the transcription of genes involved in cell cycle pro-
gression (cyclin D1, survivin), cell survival (B-cell lymphoma 2), 
angiogenesis (vascular endothelia growth factor a), and immune 
suppression [programed death ligand 1 (PD-L1)] (48, 49). These 
data suggest that the immune cells infiltrating tumor microen-
vironment might be the crucial determinants for influencing 
tumor biology, and the clinical outcome observed in VeriStrat 
poor classified patients. While erlotinib has no inhibitory effect 
on the stromal elements infiltrating tumor microenvironment, 
chemotherapy inhibits these cells, thus reducing tumor aggres-
siveness and prolonging survival.
Combinatorial strategies, including second-line docetaxel 
chemotherapy with the EGFR monoclonal antibody cetuximab, 
have been evaluated, with poor results. The greatest benefit 
was observed in those who continued previous EGFR-TKIs for 
≥ 6 months (50).
THe ROLe OF eGFR–TKis iN PaTieNTS 
wiTH SQUaMOUS HiSTOLOGY
In the field of lung squamous cell carcinoma (LSCC), less progress 
has been made. Although molecular alterations in LSCC have 
been described, effective targeted therapies have not yet been 
developed (51). These potentially targetable molecular altera-
tions include phosphoinositide 3-kinase (PIK3CA), fibroblast 
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growth factor receptor 1 (FGFR1), or c-MET amplification and 
discoidin domain receptor tyrosine kinase 2 mutations, though 
none of these biomarkers have been validated in the clinical set-
ting (52). The EGFR gene is commonly overexpressed in patients 
with LSCC (53), and two monoclonal anti-EGFR antibodies, 
cetuximab and necitumumab, in combination with platinum-
based chemotherapy in the first-line setting, have demonstrated 
improved survival in phase III studies (54, 55).
Based on these data, recently, the irreversible ErbB-family 
inhibitor afatinib has been compared with erlotinib in the phase 
III Lux-Lung 8 trial, enrolling 795 squamous patients, previously 
progressed on platinum-based chemotherapy (Table  2) (40). 
The primary end-point was PFS and the primary objective was 
to demonstrate a 29% reduction in the risk of progression with 
afatinib over erlotinib. Afatinib significantly prolonged PFS 
and OS, health-related QoL outcomes, and symptoms control. 
Archived tumor tissue was collected. Six percent of the patients 
carried EGFR activating mutations, and another six percent 
harbored EGFR amplification.
Even though, based on these results, afatinib may represent 
an additional option for the treatment of LSCC, and it has been 
approved by the Food and Drug Administration (FDA) for the 
treatment of squamous NSCLC progressing after platinum-based 
chemotherapy, the new programed death 1 (PD-1) and PD-L1 
inhibitors have dramatically changed the therapeutic algorithm 
of patients with squamous histology and represent the first thera-
peutic choice for second-line treatment.
COMMeNTS aND FUTURe 
PeRSPeCTiveS
New options have emerged in the second-line armamentarium 
for the treatment of patients with NSCLC, including immune 
checkpoint inhibitors and antiangiogenic agents. The genome 
instability of cancer cells (56) favors the development of immu-
nogenic clones (57). The antigen presenting cells (APC) or the 
dendritic cells recognize the tumor antigens, which are presented 
to the T cell receptors, that once activated on CD8+ T cells 
induce the killing of tumor cells. Inhibitory pathways have been 
selected to switch off the duration of the immune responses and 
prevent the tissue damage. Tumor cells take advantage of these 
inhibitory pathways to escape immune recognition and continue 
to proliferate. The binding of PD-1, expressed on activated T 
cells, tumor-infiltrating lymphocytes, and T regulatory cells, 
with PD-L1 or PD-L2, located on APC or tumor cells favors the 
T cells apoptosis and decrease cytokines production, thus modu-
lating the immune system activation (58). Agents targeting the 
PD-1 axis suppress the inhibitory pathways responsible for the 
induction of the immune tolerance, resulting in the restoration 
of T cells antitumor activity. Based on the results from the phase 
III CheckMate-017 and CheckMate 057 trials, showing the OS 
improvement of the PD-1 inhibitor nivolumab over docetaxel in 
squamous and non-squamous patients, respectively, nivolumab 
was granted approval by the FDA and the European Medicine 
Agency (EMA) (59, 60). Moreover, recently, the phase III OAK 
study, comparing docetaxel with the PD-L1 inhibitor atezolizumab, 
showed a significant survival improvement of 27% in patients 
receiving atezolizumab, leading to atezolizumab FDA approval 
for the treatment of second-line NSCLC patients. Similarly, the 
phase II–III KEYNOTE-010 study, comparing the PD-1 inhibitor 
pembrolizumab with docetaxel in NSCLC patients with PD-L1 
expression on at least 1% of tumor cells, showed that OS was 
significantly longer for pembrolizumab vs docetaxel (61). Among 
patients with at least 50% of tumor cells expressing PD-L1, both 
OS and PFS were significantly longer with pembrolizumab than 
docetaxel, thus determining the approval of pembrolizumab by 
EMA for the treatment of second-line NSCLC patients, positive 
for PD-L1 expression.
Another attractive therapeutic target is represented by angio-
genesis, involved in the development and progression of NSCLC. 
Angiogenesis acts as one of the essential alterations occurring in 
cells during malignant transformation (56), since the delivery 
of oxygen and nutrients, provided by blood vessels, is required 
for cell survival and proliferation. Different molecules, inhibit-
ing the angiogenic regulators, have been tested in combination 
with second-line chemotherapy (pemetrexed and docetaxel) in 
patients with NSCLC, but with disappointing results (62). Only 
recently, two drugs, interfering with the angiogenic pathways, 
nintedaninb and ramucirumab, have received the regulatory 
approval in association with docetaxel in the second-line setting.
Nintedanib is an oral triple angiokinase inhibitor, hindering 
the vascular endothelial growth factor receptor (VEGFR1–3), 
the FGFR1-3, the platelet-derived growth factor receptors 
(PDGFRα/β), fms-like tyrosine kinase 3 and members of the Src 
family (Src, Lyn, Lck) (63). Based on the results from the LUME 
Lung 1 study (64), showing a PFS improvement in patients receiv-
ing nintedanib in combination with docetaxel and a significantly 
prolonged OS in the subgroup of patients with adenocarcinoma, 
who had progressed within 9 months from the beginning of first-
line treatment, the EMA approved the use of nintedanib for the 
treatment of locally advanced or metastatic patients with lung 
adenocarcinoma after platinum recurrence.
Ramucirumab is an IgG1 monoclonal antibody, targeting 
the extracellular domain of the VEGFR-2, thus preventing the 
binding of VEGF ligands and hindering receptor activation (65). 
When associated with docetaxel, it improves both PFS and OS 
(66). These clinically meaningful findings led FDA and EMA 
to expand the indication of ramucirumab, previously approved 
for the treatment of gastric cancer, to include the treatment of 
metastatic NSCLC.
Emerging evidence that pro-angiogenic factors have immuno-
suppressive activity has suggested that agents targeting angiogen-
esis may be potentially synergistic with immunotherapy (67–69). 
Data from literature indicate that VEGF influences lymphocyte 
trafficking, stimulates T regulatory cells and myeloid-derived 
suppressor cells, and inhibits T-cell development, thus favoring 
tumor immune escape (70–72). Moreover, it has been reported 
that immunotherapies can also be antiangiogenic. Different 
phase I trials exploring the safety and efficacy of combination 
regimens are currently ongoing in different types of tumors, 
including NSCLC.
However, based on the recent results from the Phase III 
KEYNOTE-024 study, showing doubling PFS and ORR in favor 
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of pembrolizumab- vs cisplatin-based first-line chemotherapy in 
patients with PD-L1 expression on at least 50% of tumor cells 
(73), and the Phase II KEYNOTE-021 trial, demonstrating a 
significant PFS and ORR improvement when pembrolizumab 
was combined with carboplatin pemetrexed chemotehrapy, 
compared with chemotherapy alone (74), it is supposed that 
PD-1 or PD-L1 inhibitors alone or in combination with chemo-
therapy will become the standard of care for first-line treatment 
of NSCLC patients. As a consequence, clinicians will deal with 
new challenges for the definition of the second-line treatment 
algorithm.
Our knowledge on cancer immunology is not fully complete, 
and it is still not clear how to select those patients who benefit 
more from therapy with immune checkpoint inhibitors. Different 
studies are ongoing, and the predictive role of PD-L1 expres-
sion, evaluated by immunohistochemistry, is the focus of much 
research. Different PD-L1 antibodies, with different cutoff levels, 
have been selected according to the different PD-1 or PD-L1 
inhibitors evaluated in the clinical trials. Recently, thanks to the 
collaboration between academy, pharmaceutical, and diagnostic 
companies, there has been an attempt to compare and explore 
the differences and the similarities between the PD-L1 diagnostic 
assays (75). A weak correlation was found. Other markers are 
under evaluation. Data from retrospective analyses indicate that 
tumors with a high mutational burden, abundant neoantigens, 
and micro-satellite high status are associated with a good response 
to anti-PD-1/PD-L1 therapy, but additional studies are warranted 
(76–79).
In conclusion, new agents have been developed and approved 
for the treatment of NSCLC patients without oncogene-addicted 
tumors, after platinum-based chemotherapy progression, thus 
improving the number and efficacy of therapeutic opportuni-
ties, but increasing the complexity of the therapeutic selection. 
Currently, the most remarkable challenge remains the lack of 
predictive biomarkers, able to identify which patients might gain 
most benefit from these agents.
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